Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial of KME-0584 for the treatment of relapsed/refractory (R/R) AML and high-risk (HR) MDS patients

Next Previous
Trial Profile

A phase 1 trial of KME-0584 for the treatment of relapsed/refractory (R/R) AML and high-risk (HR) MDS patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KME 0584 (Primary) ; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions

Most Recent Events

  • 20 Feb 2024 New trial record
  • 15 Feb 2024 According to a Kurome Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for KME-0584, allowing the company to proceed with a Ph1 clinical trial in relapsed/refractory (R/R) AML and high-risk (HR) MDS patients.
  • 15 Feb 2024 According to a Kurome Therapeutics media release, company plans to initiate the clinical trial in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top